Promising Progress With ViroMed, Corestem’s Gene/Cell ALS Therapies
This article was originally published in PharmAsia News
Executive Summary
Two South Korean bioventures have highlighted positive clinical progress for their gene- and cell-based novel therapies for ALS at the recent ALS/MND International Symposium in Orlando, with ViroMed unveiling the results of a Phase I/II US study for VM202 and Corestem presenting a Phase II study for Neuronata-R, the world's first commercialized stem cell therapy for the debilitating disease.
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Korea Govt Partners With J&J To Bring In Local JLABS Site
In collaboration with the national health ministry, J&J’s JLAB program is coming to South Korea as its third destination in Asia, underscoring the country’s increasing need to access multinationals’ know-how and its growing impact on the global biotech landscape and innovation.
Could ASEAN Become Next Priority For Korean Pharma Firms?
Southeast Asia has so far not been a priority market for South Korean pharma firms, largely because of challenges such as access and affordability for patients. But a Deloitte executive suggested at a recent seminar that technology-based medicines, for example using next-generation formulation technologies, could be an initial focus for Korean firms looking to enter the rapidly growing ASEAN grouping.